Aug 4 (Reuters) - Sol Gel Technologies Ltd SLGL.O :
* SOL-GEL TECHNOLOGIES REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* Q2 REVENUE $3.5 MILLION VERSUS $900,000
* RECEIVES $3.5 MILLION MILESTONE PAYMENT FROM COMMERCIAL
PARTNER
GALDERMA HOLDING SA ("GALDERMA") FOR FDA APPROVAL OF EPSOLAY
* CASH RUNWAY EXPECTED TO EXTEND THROUGH END OF 2023
* QTRLY LOSS PER SHARE $0.53
* Q2 EARNINGS PER SHARE VIEW $-0.10, REVENUE VIEW $4.6
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nGNX60lGgc
Further company coverage: SLGL.O